MedAvail (MDVLQ) 10-Q 13 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 11, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-36533
Entity Registrant Name	MEDAVAIL HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772394
Entity Address, Address Line One	6665 Millcreek Dr.
Entity Address, Address Line Two	Unit 1
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5N 5M4
City Area Code	905
Local Phone Number	812-0023
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MDVL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		70,555,977
Entity Central Index Key	0001402479
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Current Fiscal Year End Date	--12-31

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,274	$ 19,689
Restricted cash	676	400
Accounts receivable (net of allowance for doubtful accounts of $96 thousand for March 31, 2022, $66 thousand for December 31, 2021)	1,748	1,189
Inventories	5,088	3,916
Prepaid expenses and other current assets	3,105	2,191
Total current assets	15,891	27,385
Property, plant and equipment, net	6,175	5,692
Intangible assets, net	2,765	2,300
Right-of-use assets	2,628	2,538
Other assets	233	228
Total assets	27,692	38,143
Current liabilities:
Accounts payable and accrued liabilities	8,527	6,740
Deferred revenue	107	83
Current portion of lease obligations	733	682
Total current liabilities	9,367	7,505
Long-term debt, net	9,608	9,538
Long-term portion of lease obligations	2,102	2,027
Total liabilities	21,077	19,070
Commitments and contingencies
Stockholders' deficit:
#REF!	33	33
Warrants	1,373	1,373
Additional paid-in-capital	217,249	216,685
Accumulated other comprehensive loss	(6,928)	(6,928)
Accumulated deficit	(205,112)	(192,090)
Total stockholders' equity	6,615	19,073
Total liabilities and stockholders' equity	$ 27,692	$ 38,143

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 96	$ 66
Common shares, par value (in USD per share)	$ 0.001	$ 0.001
Common shares, authorized (in shares)	100,000,000	100,000,000
Common shares, issued (in shares)	32,908,922	32,902,048
Common shares, outstanding (in shares)	32,908,922	32,902,048

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 9,114	$ 4,027
Cost of products sold and services:
Total cost of products sold and services	8,613	3,707
Operating expense:
Pharmacy operations	3,929	2,593
General and administrative	6,535	5,676
Selling and marketing	2,313	1,534
Research and development	493	168
Total operating expense	13,270	9,971
Operating loss	(12,769)	(9,651)
Other gain (loss), net	0	161
Interest income	1	40
Interest expense	(254)	(2)
Loss before income taxes	(13,022)	(9,452)
Income tax expense	0	0
Net loss	(13,022)	(9,452)
Comprehensive loss	$ (13,022)	$ (9,452)
Net loss per share - basic (in USD per share)	$ (0.40)	$ (0.27)
Net loss per share - diluted (in USD per share)	$ (0.40)	$ (0.27)
Weighted average shares outstanding - basic (in shares)	32,921,969	34,439,953
Weighted average shares outstanding - diluted (in shares)	32,921,969	34,439,953
Pharmacy and hardware revenue
Revenue:
Total revenue	$ 9,014	$ 3,781
Cost of products sold and services:
Total cost of products sold and services	8,563	3,526
Service revenue
Revenue:
Total revenue	100	246
Cost of products sold and services:
Total cost of products sold and services	$ 50	$ 181

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares	Warrants	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance at beginning of period (in shares) at Dec. 31, 2020		31,816,020
Balance at beginning of period at Dec. 31, 2020	$ 61,067	$ 32	$ 2,614	$ 213,624	$ (148,275)	$ (6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(9,452)				(9,452)
Shares issued for options exercises (in shares)		120,924
Shares issued for options exercises	201			201
Exercise of warrants (in shares)		2,954
Exercise of warrants	5		(35)	40
Share-based compensation	260			260
Balance at end of period (in shares) at Mar. 31, 2021		31,939,898
Balance at end of period at Mar. 31, 2021	52,081	$ 32	2,579	214,125	(157,727)	(6,928)
Balance at beginning of period (in shares) at Dec. 31, 2021		32,902,048
Balance at beginning of period at Dec. 31, 2021	19,073	$ 33	1,373	216,685	(192,090)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (13,022)				(13,022)
Shares issued for vested RSUs (in shares)		6,874
Shares issued for options exercises (in shares)	0
Share-based compensation	$ 564			564
Balance at end of period (in shares) at Mar. 31, 2022		32,908,922
Balance at end of period at Mar. 31, 2022	$ 6,615	$ 33	$ 1,373	$ 217,249	$ (205,112)	$ (6,928)

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (13,022)	$ (9,452)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	286	295
Amortization of intangible and leased assets	312	207
Bad debt and other non cash receivables adjustments	30	15
Term loan discount amortization and interest accretion on debt	70	2
Share-based compensation expense	564	260
PPP loan forgiveness gain	0	(161)
Changes in operating assets and liabilities:
Change in accounts receivable	(589)	101
Change in inventory	(1,601)	(360)
Change in prepaid expenses and other current assets	(914)	79
Change in accounts payable, accrued expenses and other liabilities	1,705	(639)
Change in deferred revenue	24	(13)
Change in operating lease liability due to cash payments	(129)	(164)
Net cash used in operating activities	(13,264)	(9,830)
Cash flows from investing activities:
Purchase of property, plant and equipment	(343)	(260)
Payment of security deposits	(5)	0
Purchase of intangible assets and other assets	(504)	(452)
Net cash used in investing activities	(852)	(712)
Cash flows from financing activities:
Issuance of common shares upon exercise of options and warrants	0	206
Payments on finance lease obligations	(23)	(17)
Net cash (used in) provided by financing activities	(23)	189
Net decrease in cash, cash equivalents and restricted cash	(14,139)	(10,353)
Cash, cash equivalents and restricted cash at beginning of period	20,089	57,996
Cash, cash equivalents and restricted cash at end of period	5,950	47,643
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment	429	58
Property, plant and equipment transferred to intangible assets	0	36
Purchase of property, plant and equipment in accounts payable	122	0
Purchase of intangible assets in accounts payable	326	0
Lease liabilities arising from obtaining right of use assets:
Operating leases	205	279
Finance leases	$ 73	$ 0

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONSMedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation formerly known as MYOS RENS Technology, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, kiosk and drive-thru solution. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. The Company also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	GOING CONCERN Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to our ability to continue as a going concern. If substantial doubt does exist, then management should determine if there are plans in place which alleviate that doubt. Since inception through March 31, 2022, the Company continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for three months ended March 31, 2022 and 2021 was $13.3 million and $9.8 million, respectively. As of March 31, 2022, the Company had $5.3 million in cash and cash equivalents and an accumulated deficit of $205.1 million. In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in anticipated gross proceeds to be received upon the second close expected to occur on July 1, 2022, subject to the satisfaction or waiver of the conditions to closing, before deducting placement agent commissions and other offering expenses. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 13 for further information regarding the private placement warrants. Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is substantial doubt as to the Company’s ability to continue as a going concern. The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which the Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above, the Company raised $40.0 million in gross proceeds through a private placement. There can be no assurance that the steps management is taking will be successful. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development and expansion plans. The consolidated condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the ability to raise significant additional funding.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited consolidated condensed financial statements as of March 31, 2022 and for the three months ended March 31, 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in- process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary. Risks and uncertainties relating to COVID-19 The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated condensed financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements. Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. Reclassifications During the fourth quarter of 2021, management reclassified certain operating expenses to reflect the costs attributable to pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact on the operating loss subtotal within the consolidated statements of operations and comprehensive loss. The effect of the reclassifications within the consolidated condensed statement of operations and comprehensive loss for 2021 is as follows (in thousands): Three Months Ended March 31, 2021 Current presentation As previously reported Change Pharmacy operations $ 2,593 $ 1,911 $ 682 General and administrative 5,676 6,515 (839) Selling and marketing 1,534 1,377 157 $ 9,803 $ 9,803 $ —

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated condensed financial statements and related disclosures. Recently Adopted Accounting Standards There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding up to when they were exercised. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding During the three months ended March 31, 2022 and 2021, there was no dilutive effect from stock options or other warrants due to the Company’s net loss position. Weighted average shares for historical periods have been adjusted for the effect of the 1.26 for 1 split on November 17, 2020. The following table sets forth the computation of basic and diluted earnings per share. Three Months Ended March 31, (in thousands) 2022 2021 Net loss - basic and diluted $ (13,022) $ (9,452) Weighted average shares - basic and diluted 32,921,969 34,439,953 Net loss per share - basic and diluted $ (0.40) $ (0.27) As of March 31, 2022 and 2021, there were 4.4 million and 2.5 million, respectively, of option awards outstanding that were not included in the diluted shares calculation because their inclusion would have been antidilutive.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) March 31, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,274 $ 5,274 $ — $ — Restricted cash 676 676 — — Total assets $ 5,950 $ 5,950 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ — The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities, a Level 2 input. Refer to Note 8, Debt, for further information.

BALANCE SHEET AND OTHER INFORMA

BALANCE SHEET AND OTHER INFORMATION	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET AND OTHER INFORMATION	BALANCE SHEET AND OTHER INFORMATION Restricted cash The Company considers cash to be restricted when withdrawal or general use is legally restricted. During the year ended December 31, 2021, the Company recovered the prior $0.06 million restricted cash balance that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.68 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in the balance for cash presented in the statements of cash flows. Inventory The following table presents detail of inventory balances: March 31, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 1,589 $ 1,201 Pharmaceuticals 2,904 2,150 Spare parts 595 565 Total inventory $ 5,088 $ 3,916 Pharmaceutical inventory was recognized in pharmacy and hardware cost of products sold at $7.9 million and $3.1 million during the three months ended March 31, 2022 and 2021, respectively. MedCenter hardware was recognized in pharmacy and hardware cost of products sold at $0.1 million and $0.2 million during the three months ended March 31, 2022 and 2021, respectively. Property, plant and equipment The following tables present property, plant and equipment balances: Estimated useful lives March 31, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 6,861 $ 5,875 IT equipment 1 - 3 years 2,373 2,361 Leasehold improvements lesser of useful life or term of lease 903 880 General plant and equipment 5 - 8 years 603 603 Office furniture and equipment 5 - 8 years 464 394 Vehicles 5 years 54 54 Construction-in-process 680 1,021 Total historical cost 11,938 11,188 Accumulated depreciation (5,763) (5,496) Total property, plant and equipment, net $ 6,175 $ 5,692 Depreciation expense of property and equipment was $0.3 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively. Depreciation expense included in pharmacy and hardware cost of products sold was $0.03 million and $0.05 million for the three months ended March 31, 2022 and 2021, respectively. Intangible assets The following table presents intangible asset balances: March 31, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,064 4,475 Website and mobile application 583 583 Total intangible assets 9,504 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (2,299) (2,175) Website and mobile application (583) (583) Total accumulated amortization (6,739) (6,615) Total intangible assets, net $ 2,765 $ 2,300 Amortization expense of intangible assets was $0.12 million and $0.03 million for the three months ended March 31, 2022 and 2021, respectively, and are included in operating expenses. Lessee leases Balance sheet amounts for lease assets and leases liabilities are as follows: March 31, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,416 $ 2,376 Finance 212 162 Total assets $ 2,628 $ 2,538 Liabilities: Operating: Current $ 626 $ 599 Long-term 1,996 1,947 Finance: Current 107 83 Long-term 106 80 Total liabilities $ 2,835 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: March 31, December 31, (in thousands) 2022 2021 Finance leases: Weighted-average remaining lease term (years) 2.2 1.5 Weighted-average discount rate 8.4 % 8.8 % Operating leases: Weighted-average remaining lease term (years) 4.1 4.2 Weighted-average discount rate 6.9 % 6.9 % Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2022 $ 602 2023 757 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 3,042 Less: present value discount (420) Total leases $ 2,622 Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2022 $ 92 2023 91 2024 47 2025 5 2026 — 2027 — Thereafter — Total finance lease payments 235 Less: imputed interest (22) Total leases $ 213 Operating lease expense was $0.2 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
DEBT	DEBT The following table presents debt balances at March 31, 2022 and December 31, 2021: March 31, December 31, (in thousands) 2022 2021 Term loan 10,100 10,070 Term loan issuance costs, net (492) (532) Total debt, net 9,608 9,538 Less short term debt — — Long-term debt, net $ 9,608 $ 9,538 Term loan The Term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (7.25% at March 31, 2022). The Company could borrow up to an additional $20.0 million in aggregate term loans on or before April 30, 2022, however this option was not used and expired.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company incurred minimal income tax expense for the three months ended March 31, 2022, due to ongoing losses and minimum state income tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses. As of March 31, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation. The Demands and the Complaints that comprise the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties. MYOS and MAI believe that the claims asserted in the Litigation are without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. The remainder of the Litigation remains outstanding. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or is required.

SHARE-BASED COMPENSATION EXPENS

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
SHARE-BASED COMPENSATION EXPENSE AND WARRANTS	SHARE-BASED COMPENSATION AND WARRANTS Share-based compensation The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended March 31, 2022 2021 Share-based compensation $ 564 $ 260 The share-based compensation expense for the three months ended March 31, 2022, included $0.03 million from 2020 ESPP expense. Expense remaining to be recognized for unvested option awards from the 2012, 2018, and 2020 plans as of March 31, 2022 was $2.7 million, which will be recognized on a weighted average basis over the next 3.2 years. Expense remaining to be recognized for unvested RSU awards was $2.7 million will be recognized on a weighted average basis over the next 2.7 years. The following table presents the Company's outstanding option awards activity during the three months ended March 31, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 31 Granted 1,749,015 1.18 0.85 — Exercised/Released — — — — Expired (117,730) 2.11 1.15 — Forfeited (127,617) 3.18 1.66 — Outstanding, end of period 4,352,571 $ 2.15 $ 1.21 8.54 $ 40 Vested and exercisable, end of the period 1,710,753 2.17 1.07 6.88 — Vested and unvested exercisable, end of the period 1,710,753 2.17 1.07 6.88 — Vested and expected to vest, end of the period 4,095,070 2.16 1.21 8.47 38 During the three months ended March 31, 2022, the Company granted approximately 1.2 million restricted stock units or RSUs to employees with a weighted average fair value of $1.20 per RSU and total aggregate intrinsic value of $1.4 million. 12,048 RSUs vested and 26,074 RSU's were forfeited during the three months ended March 31, 2022. As of March 31, 2022 and December 31, 2021, there was an aggregate of 2.1 million and 3.4 million shares of common stock, respectively, available for grant under the 2020 Plan. In April 2022, the Company adopted the MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock, and 426,500 RSUs. The inducement stock options have an exercise price of $1.96, and 25% of the shares vest on the one year anniversary of the date that employment commenced, and an additional one forty-eighth (1/48th) of the shares vest monthly thereafter. The inducement RSUs vest at one-third (1/3rd) of the shares on the first, second and third yearly anniversaries of March 1, 2022. Warrants During the three months ended March 31, 2022 no warrants were issued or exercised. There were 626,339 related party warrants outstanding as of March 31, 2022.

REVENUE AND SEGMENT REPORTING

REVENUE AND SEGMENT REPORTING	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
REVENUE AND SEGMENT REPORTING	REVENUE AND SEGMENT REPORTING Operating segments are the individual operations that the chief operating decision maker, or CODM, who is our chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses. The Company has the following two reportable segments: Retail Pharmacy Services Segment Retail Pharmacy Services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts. Pharmacy Technology Segment The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements. The following table presents revenue and costs of products sold and services by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Total Three Months Ended March 31, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 8,849 $ — $ 8,849 Hardware — 56 56 Subscription — 109 109 Total pharmacy and hardware revenue 8,849 165 9,014 Service revenue: Software integration — — — Software — 48 48 Maintenance and support — 32 32 Installation — 6 6 Professional services and other — 14 14 Total service revenue — 100 100 Total revenue 8,849 265 9,114 Cost of products sold and services 8,482 131 8,613 Segment gross profit $ 367 $ 134 501 Operating Expense: Pharmacy operations 3,929 General and administrative 6,535 Selling and marketing 2,313 Research and development 493 Total operating expense 13,270 Operating loss $ (12,769) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended March 31, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 3,418 $ — $ 3,418 Hardware — 241 241 Subscription — 122 122 Total pharmacy and hardware revenue 3,418 363 3,781 Service revenue: Software integration — — — Software — 33 33 Maintenance and support — 31 31 Installation — 16 16 Professional services and other — 166 166 Total service revenue — 246 246 Total revenue 3,418 609 4,027 Cost of products sold and services 3,329 378 3,707 Segment gross profit $ 89 $ 231 320 Operating Expense: Pharmacy operations 2,593 General and administrative 5,676 Selling and marketing 1,534 Research and development 168 Total operating expense 9,971 Operating loss $ (9,651) The following table presents assets and liabilities by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Corporate Total March 31, 2022 Assets $ 16,323 $ 6,661 $ 4,708 $ 27,692 Liabilities $ 6,705 $ 4,183 $ 10,189 $ 21,077 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets, in thousands: March 31, December 31, 2022 2021 Long-lived assets: United States $ 8,383 $ 7,675 Canada 420 555 Total long-lived assets $ 8,803 $ 8,230

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On March 30, 2022, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investors in a private placement, or the Private Placement, up to 47.1 million shares, or the Shares, of the Company’s Common Stock, and to issue warrants, or the Warrants, to purchase up to 23.5 million shares of Common Stock, or Warrant Shares. The Shares and the Warrants were or will be sold at two closings as further described below, at a price per share of $1.0625. Each Investor purchasing Shares in the Private Placement was or will also be issued a Warrant to purchase that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full by the Investors, the Company would receive additional gross proceeds of up to $29.4 million. In addition, the Warrant terms provide the Company with a call option to force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants, and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options, approximately $19.6 million in additional equity could be raised. On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of Common Stock for $40.0 million in gross proceeds, and Warrants exercisable for up to 18.8 million Warrant Shares were sold and issued by the Company, and pursuant to which the Company received $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses. A second and final closing is expected to occur in July 2022, subject to the satisfaction or wavier of certain conditions to closing, pursuant to which the Company shall sell and issue, and the Investors shall purchase, an additional 9.4 million shares of Common Stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrant Shares.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated condensed financial statements as of March 31, 2022 and for the three months ended March 31, 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-
Principles of consolidation	Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
Recently Adopted Accounting Standards	Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated condensed financial statements and related disclosures. Recently Adopted Accounting Standards There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The effect of the reclassifications within the consolidated condensed statement of operations and comprehensive loss for 2021 is as follows (in thousands): Three Months Ended March 31, 2021 Current presentation As previously reported Change Pharmacy operations $ 2,593 $ 1,911 $ 682 General and administrative 5,676 6,515 (839) Selling and marketing 1,534 1,377 157 $ 9,803 $ 9,803 $ —

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Warrants Included in Earnings per Share	The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding up to when they were exercised. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding
Schedule of Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share. Three Months Ended March 31, (in thousands) 2022 2021 Net loss - basic and diluted $ (13,022) $ (9,452) Weighted average shares - basic and diluted 32,921,969 34,439,953 Net loss per share - basic and diluted $ (0.40) $ (0.27)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) March 31, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,274 $ 5,274 $ — $ — Restricted cash 676 676 — — Total assets $ 5,950 $ 5,950 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ —

BALANCE SHEET AND OTHER INFOR_2

BALANCE SHEET AND OTHER INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	The following table presents detail of inventory balances: March 31, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 1,589 $ 1,201 Pharmaceuticals 2,904 2,150 Spare parts 595 565 Total inventory $ 5,088 $ 3,916
Schedule of Property, Plant and Equipment and Useful Lives	The following tables present property, plant and equipment balances: Estimated useful lives March 31, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 6,861 $ 5,875 IT equipment 1 - 3 years 2,373 2,361 Leasehold improvements lesser of useful life or term of lease 903 880 General plant and equipment 5 - 8 years 603 603 Office furniture and equipment 5 - 8 years 464 394 Vehicles 5 years 54 54 Construction-in-process 680 1,021 Total historical cost 11,938 11,188 Accumulated depreciation (5,763) (5,496) Total property, plant and equipment, net $ 6,175 $ 5,692
Schedule of Finite-Lived Intangible Assets	The following table presents intangible asset balances: March 31, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,064 4,475 Website and mobile application 583 583 Total intangible assets 9,504 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (2,299) (2,175) Website and mobile application (583) (583) Total accumulated amortization (6,739) (6,615) Total intangible assets, net $ 2,765 $ 2,300
Schedule of Lease Assets and Liabilities	Balance sheet amounts for lease assets and leases liabilities are as follows: March 31, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,416 $ 2,376 Finance 212 162 Total assets $ 2,628 $ 2,538 Liabilities: Operating: Current $ 626 $ 599 Long-term 1,996 1,947 Finance: Current 107 83 Long-term 106 80 Total liabilities $ 2,835 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: March 31, December 31, (in thousands) 2022 2021 Finance leases: Weighted-average remaining lease term (years) 2.2 1.5 Weighted-average discount rate 8.4 % 8.8 % Operating leases: Weighted-average remaining lease term (years) 4.1 4.2 Weighted-average discount rate 6.9 % 6.9 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2022 $ 602 2023 757 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 3,042 Less: present value discount (420) Total leases $ 2,622
Schedule of Maturities of Finance Lease Liabilities	Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2022 $ 92 2023 91 2024 47 2025 5 2026 — 2027 — Thereafter — Total finance lease payments 235 Less: imputed interest (22) Total leases $ 213

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt	The following table presents debt balances at March 31, 2022 and December 31, 2021: March 31, December 31, (in thousands) 2022 2021 Term loan 10,100 10,070 Term loan issuance costs, net (492) (532) Total debt, net 9,608 9,538 Less short term debt — — Long-term debt, net $ 9,608 $ 9,538

SHARE-BASED COMPENSATION EXPE_2

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of MedAvail Share-based Compensation Expense	The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended March 31, 2022 2021 Share-based compensation $ 564 $ 260
Schedule of Outstanding Awards Activity	The following table presents the Company's outstanding option awards activity during the three months ended March 31, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 31 Granted 1,749,015 1.18 0.85 — Exercised/Released — — — — Expired (117,730) 2.11 1.15 — Forfeited (127,617) 3.18 1.66 — Outstanding, end of period 4,352,571 $ 2.15 $ 1.21 8.54 $ 40 Vested and exercisable, end of the period 1,710,753 2.17 1.07 6.88 — Vested and unvested exercisable, end of the period 1,710,753 2.17 1.07 6.88 — Vested and expected to vest, end of the period 4,095,070 2.16 1.21 8.47 38

REVENUE AND SEGMENT REPORTING (

REVENUE AND SEGMENT REPORTING (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Revenue and Costs of Sales by Segment	The following table presents revenue and costs of products sold and services by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Total Three Months Ended March 31, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 8,849 $ — $ 8,849 Hardware — 56 56 Subscription — 109 109 Total pharmacy and hardware revenue 8,849 165 9,014 Service revenue: Software integration — — — Software — 48 48 Maintenance and support — 32 32 Installation — 6 6 Professional services and other — 14 14 Total service revenue — 100 100 Total revenue 8,849 265 9,114 Cost of products sold and services 8,482 131 8,613 Segment gross profit $ 367 $ 134 501 Operating Expense: Pharmacy operations 3,929 General and administrative 6,535 Selling and marketing 2,313 Research and development 493 Total operating expense 13,270 Operating loss $ (12,769) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended March 31, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 3,418 $ — $ 3,418 Hardware — 241 241 Subscription — 122 122 Total pharmacy and hardware revenue 3,418 363 3,781 Service revenue: Software integration — — — Software — 33 33 Maintenance and support — 31 31 Installation — 16 16 Professional services and other — 166 166 Total service revenue — 246 246 Total revenue 3,418 609 4,027 Cost of products sold and services 3,329 378 3,707 Segment gross profit $ 89 $ 231 320 Operating Expense: Pharmacy operations 2,593 General and administrative 5,676 Selling and marketing 1,534 Research and development 168 Total operating expense 9,971 Operating loss $ (9,651)
Schedule of Assets and Liabilities by Segment	The following table presents assets and liabilities by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Corporate Total March 31, 2022 Assets $ 16,323 $ 6,661 $ 4,708 $ 27,692 Liabilities $ 6,705 $ 4,183 $ 10,189 $ 21,077 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets, in thousands: March 31, December 31, 2022 2021 Long-lived assets: United States $ 8,383 $ 7,675 Canada 420 555 Total long-lived assets $ 8,803 $ 8,230

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($) $ in Thousands	Jul. 01, 2022	Apr. 04, 2022	Jul. 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Operating cash flows					$ (13,264)	$ (9,830)
Cash and cash equivalents					5,274		$ 19,689
Accumulated deficit					$ 205,112		192,090
Term loan | Secured Debt
Debt Instrument [Line Items]
Proceeds from debt							$ 10,000
Private Placement | Forecast
Debt Instrument [Line Items]
Gross proceeds from private placement	$ 10,000		$ 10,000
Private Placement | Subsequent Event
Debt Instrument [Line Items]
Gross proceeds from private placement		$ 40,000		$ 40,000

BASIS OF PRESENTATION - Reclass

BASIS OF PRESENTATION - Reclassifications (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations	$ 3,929	$ 2,593
General and administrative	6,535	5,676
Selling and marketing	$ 2,313	1,534
Total		9,803
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		1,911
General and administrative		6,515
Selling and marketing		1,377
Total		9,803
Change
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		682
General and administrative		(839)
Selling and marketing		157
Total		$ 0

EARNINGS (LOSS) PER SHARE - War

EARNINGS (LOSS) PER SHARE - Warrants Included in Earnings per Share (Details)	3 Months Ended
	Mar. 31, 2022shares
Warrants Issued May 9, 2018
Common
Warrants (in shares)	118,228
Warrants Issued February 11, 2020
Common
Warrants (in shares)	309,698
Warrants Issued June 29, 2020
Common
Warrants (in shares)	84,911
Warrants Issued November 18, 2020
Common
Warrants (in shares)	39,208
Warrants Issued November 18, 2020, Outstanding
Common
Warrants (in shares)	19,310

EARNINGS (LOSS) PER SHARE - Nar

EARNINGS (LOSS) PER SHARE - Narrative (Details) shares in Millions	Nov. 17, 2020	Mar. 31, 2022shares	Mar. 31, 2021shares
Earnings Per Share [Abstract]
Stock split, conversion ratio	1.26
Potentially dilutive option awards excluded from earnings per share calculation (in shares)		4.4	2.5

EARNINGS (LOSS) PER SHARE - Cal

EARNINGS (LOSS) PER SHARE - Calculation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss - basic	$ (13,022)	$ (9,452)
Net loss - diluted	$ (13,022)	$ (9,452)
Weighted average shares - basic (in shares)	32,921,969	34,439,953
Weighted average shares - diluted (in shares)	32,921,969	34,439,953
Net loss per share - basic (in USD per share)	$ (0.40)	$ (0.27)
Net loss per share - diluted (in USD per share)	$ (0.40)	$ (0.27)

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 5,274	$ 19,689
Restricted cash	676	400
Total assets	5,950	20,089
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	5,274	19,689
Restricted cash	676	400
Total assets	5,950	20,089
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	$ 0	$ 0

BALANCE SHEET AND OTHER INFOR_3

BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Inventory [Line Items]
Restricted cash	$ 676		$ 400
Depreciation of property, plant, and equipment	286	$ 295
Depreciation included in cost of sales	30	50
Amortization of intangible assets	120	30
Operating lease, expense	200	200
Pharmacy
Inventory [Line Items]
Inventory recognized as cost of sales	7,900	3,100
MedCenter
Inventory [Line Items]
Inventory recognized as cost of sales	100	$ 200
Guarantee for Purchasing Cards
Inventory [Line Items]
Cash released from restriction	60
Letter of Credit Security
Inventory [Line Items]
Restricted cash	$ 680

BALANCE SHEET AND OTHER INFOR_4

BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
MedCenter hardware	$ 1,589	$ 1,201
Pharmaceuticals	2,904	2,150
Spare parts	595	565
Total inventory	$ 5,088	$ 3,916

BALANCE SHEET AND OTHER INFOR_5

BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Historical cost	$ 11,938	$ 11,188
Accumulated depreciation	(5,763)	(5,496)
Total property, plant and equipment, net	$ 6,175	5,692
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Historical cost	$ 6,861	5,875
IT equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 2,373	2,361
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Historical cost	$ 903	880
General plant and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 603	603
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 464	394
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Historical cost	$ 54	54
Construction-in-process
Property, Plant and Equipment [Line Items]
Historical cost	$ 680	$ 1,021

BALANCE SHEET AND OTHER INFOR_6

BALANCE SHEET AND OTHER INFORMATION - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 9,504	$ 8,915
Accumulated amortization	(6,739)	(6,615)
Total intangible assets, net	2,765	2,300
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	3,857	3,857
Accumulated amortization	(3,857)	(3,857)
Software
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	5,064	4,475
Accumulated amortization	(2,299)	(2,175)
Website and mobile application
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	583	583
Accumulated amortization	$ (583)	$ (583)

BALANCE SHEET AND OTHER INFOR_7

BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Operating	$ 2,416	$ 2,376
Finance	212	162
Total assets	2,628	2,538
Operating:
Current	626	599
Long-term	1,996	1,947
Finance:
Current	107	83
Long-term	106	80
Total liabilities	$ 2,835	$ 2,709

BALANCE SHEET AND OTHER INFOR_8

BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details)	Mar. 31, 2022	Dec. 31, 2021
Finance leases:
Weighted-average remaining lease term (years)	2 years 2 months 12 days	1 year 6 months
Weighted-average discount rate	8.40%	8.80%
Operating leases:
Weighted-average remaining lease term (years)	4 years 1 month 6 days	4 years 2 months 12 days
Weighted-average discount rate	6.90%	6.90%

BALANCE SHEET AND OTHER INFOR_9

BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details) $ in Thousands	Mar. 31, 2022USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2022	$ 602
2023	757
2024	617
2025	534
2026	468
2027	64
Thereafter	0
Total lease payments	3,042
Less: present value discount	(420)
Total leases	$ 2,622

BALANCE SHEET AND OTHER INFO_10

BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details) $ in Thousands	Mar. 31, 2022USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2022	$ 92
2023	91
2024	47
2025	5
2026	0
2027	0
Thereafter	0
Total finance lease payments	235
Less: imputed interest	(22)
Total leases	$ 213

DEBT - Schedule of Debt (Detail

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total debt, net	$ 9,608	$ 9,538
Less short term debt	0	0
Long-term debt, net	9,608	9,538
Term loan | Secured Debt
Debt Instrument [Line Items]
Debt instrument, gross	10,100	10,070
Term loan issuance costs, net	$ (492)	$ (532)

DEBT - Narrative (Details)

DEBT - Narrative (Details) - Term loan - Secured Debt $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Debt Instrument [Line Items]
Debt instrument, interest rate floor	7.25%
Interest rate at end of period	7.25%
Additional borrowing capacity available	$ 20
Prime Rate
Debt Instrument [Line Items]
Variable interest rate spread	4.00%

SHARE-BASED COMPENSATION EXPE_3

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Share Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Equity [Abstract]
Share-based compensation expense	$ 564	$ 260

SHARE-BASED COMPENSATION EXPE_4

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 08, 2022	Mar. 31, 2022	Apr. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized		$ 2,700
Weighted average recognition period (in years)		3 years 2 months 12 days
Aggregate shares on common stock available for grant (in shares)		2,100,000		3,400,000
Granted (in shares)		1,749,015
Exercise price (in USD per share)		$ 1.18
Warrants issued during the period (in shares)		0
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	426,500
Exercise price (in USD per share)	$ 1.96
Investors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants (in shares)		626,339
2022 Inducement Equity Incentive Plan | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance (in shares)			1,500,000
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 30
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized		$ 2,700
Weighted average recognition period (in years)		2 years 8 months 12 days
Granted (in shares)		1,200,000
Grant date fair value of awards granted (in USD per share)		$ 1.20
Aggregate intrinsic value of awards granted		$ 1,400
Number of vested awards (in shares)		12,048
Number of forfeited (in shares)		26,074
Restricted Stock Units (RSUs) | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	426,500
Restricted Stock Units (RSUs) | 2022 Inducement Equity Incentive Plan | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	33.33%
Option | Share-based Payment Arrangement, Tranche One | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	25.00%
Option | Share-based Payment Arrangement, Tranche Two | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	2.08%

SHARE-BASED COMPENSATION EXPE_5

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Awards
Outstanding awards at beginning of period (in shares)	2,848,903
Granted (in shares)	1,749,015
Exercised/released (in shares)	0
Expired (in shares)	(117,730)
Forfeited (in shares)	(127,617)
Outstanding awards at end of period (in shares)	4,352,571	2,848,903
Awards vested and exercisable (in shares)	1,710,753
Awards vested and unvested exercisable (in shares)	1,710,753
Awards vested and expected to vest (in shares)	4,095,070
Weighted Average Exercise Price
Weighted average exercise price of awards outstanding at beginning of period (in USD per share)	$ 2.78
Weighted average exercise price of awards granted (in USD per share)	1.18
Weighted average exercise price of awards exercised/released (in USD per share)	0
Weighted average exercise price of awards expired (in USD per share)	2.11
Weighted average exercise price of awards forfeited (in USD per share)	3.18
Weighted average exercise price of awards outstanding at end of period (in USD per share)	2.15	$ 2.78
Weighted average exercise price of awards vested and exercisable (in USD per share)	2.17
Weighted average exercise price of awards vested and unvested exercisable (in USD per share)	2.17
Weighted average exercise price of awards vested and expected to vest (in USD per share)	2.16
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	1.44
Grant date fair value of options granted (in USD per share)	0.85
Weighted average fair value of awards exercised/released (in USD per share)	0
Weighted average fair value of awards expired (in USD per share)	1.15
Weighted average fair value of awards forfeited (in USD per share)	1.66
Weighted average fair value of awards outstanding at end of period (in USD per share)	1.21	$ 1.44
Weighted average fair value of awards vested and exercisable (in USD per share)	1.07
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	1.07
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 1.21
Weighted Average Remaining Contractual Life (Years)
Outstanding, end of period	8 years 6 months 14 days
Vested and exercisable, end of the period	6 years 10 months 17 days
Vested and unvested exercisable, end of the period	6 years 10 months 17 days
Vested and expected to vest, end of the period	8 years 5 months 19 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period	$ 31
Aggregate intrinsic value of awards granted	0
Aggregate intrinsic value of awards exercised/released	0
Aggregate intrinsic value of awards expired	0
Aggregate intrinsic value of awards forfeited	0
Aggregate intrinsic value of awards outstanding at end of period	40	$ 31
Aggregate intrinsic value of awards vested and exercisable	0
Aggregate intrinsic value of awards vested and unvested exercisable	0
Aggregate intrinsic value of awards vested and expected to vest	$ 38

REVENUE AND SEGMENT REPORTING -

REVENUE AND SEGMENT REPORTING - Narrative (Details)	3 Months Ended
	Mar. 31, 2022segment
Segment Reporting [Abstract]
Number of reportable segments	2

REVENUE AND SEGMENT REPORTING_2

REVENUE AND SEGMENT REPORTING - Schedule of Revenue and Cost of Sales (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	$ 9,114	$ 4,027
Total cost of products sold and services	8,613	3,707
Operating expense:	501	320
Operating expense:
Pharmacy operations	3,929	2,593
General and administrative	6,535	5,676
Selling and marketing	2,313	1,534
Research and development	493	168
Total operating expense	13,270	9,971
Operating loss	(12,769)	(9,651)
Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	8,849	3,418
Total cost of products sold and services	8,482	3,329
Operating expense:	367	89
Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	265	609
Total cost of products sold and services	131	378
Operating expense:	134	231
Total pharmacy and hardware revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	9,014	3,781
Total cost of products sold and services	8,563	3,526
Total pharmacy and hardware revenue | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	8,849	3,418
Total pharmacy and hardware revenue | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	165	363
Retail pharmacy revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	8,849	3,418
Retail pharmacy revenue | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	8,849	3,418
Retail pharmacy revenue | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	56	241
Hardware | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Hardware | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	56	241
Subscription
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	109	122
Subscription | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Subscription | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	109	122
Total service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	100	246
Total cost of products sold and services	50	181
Total service revenue | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Total service revenue | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	100	246
Software integration
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Software integration | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Software integration | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	48	33
Software | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Software | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	48	33
Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	32	31
Maintenance and support | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Maintenance and support | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	32	31
Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	6	16
Installation | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Installation | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	6	16
Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	14	166
Professional services and other | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0
Professional services and other | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	$ 14	$ 166

REVENUE AND SEGMENT REPORTING_3

REVENUE AND SEGMENT REPORTING - Schedule of Assets and Liabilities by Segment (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 27,692	$ 38,143
Liabilities	21,077	19,070
Operating Segments | Retail Pharmacy Services
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	16,323	13,641
Liabilities	6,705	5,618
Operating Segments | Pharmacy Technology
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	6,661	5,222
Liabilities	4,183	3,567
Corporate
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	4,708	19,280
Liabilities	$ 10,189	$ 9,885

REVENUE AND SEGMENT REPORTING_4

REVENUE AND SEGMENT REPORTING - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	$ 8,803	$ 8,230
United States
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	8,383	7,675
Canada
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	$ 420	$ 555

SUBSEQENT EVENTS (Details)

SUBSEQENT EVENTS (Details) $ / shares in Units, shares in Millions, $ in Millions	Jul. 01, 2022USD ($)	Apr. 04, 2022USD ($)shares	Jul. 31, 2022USD ($)shares	Apr. 30, 2022USD ($)	Mar. 30, 2022USD ($)closing$ / sharesshares
Warrant Shares
Subsequent Event [Line Items]
Exercise price of warrants issued (in USD per share) | $ / shares					$ 1.25
Term of warrants (in years)					5 years
Proceeds to be received if warrants are exercised in full | $					$ 29.4
Percentage of warrants callable					66.67%
Exercise the contingent call options, additional equity | $					$ 19.6
Warrant Shares | Warrants Callable at 12 Months
Subsequent Event [Line Items]
Percentage of warrants callable					33.33%
Warrant Shares | Warrants Callable at 24 Months
Subsequent Event [Line Items]
Percentage of warrants callable					33.33%
Private Placement
Subsequent Event [Line Items]
Number of shares authorized to be sold (in shares)					47.1
Number of shares called by warrants (in shares)					23.5
Number of closings | closing					2
Sale of stock (in USD per share) | $ / shares					$ 1.0625
Warrants issued as a percentage of shares purchased					50.00%
Private Placement | Forecast
Subsequent Event [Line Items]
Number of shares sold or expected to be sold (in shares)			9.4
Gross proceeds from private placement | $	$ 10		$ 10
Number of warrants issued (in shares)			4.7
Private Placement | Subsequent Event
Subsequent Event [Line Items]
Number of shares sold or expected to be sold (in shares)		37.6
Gross proceeds from private placement | $		$ 40		$ 40
Number of warrants issued (in shares)		18.8
Proceeds from issuance of warrants | $		$ 40